LBF20107PG20: Difference between revisions
No edit summary |
No edit summary |
||
(20 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
Line 4: | Line 6: | ||
|LipidBank=XPR1799 | |LipidBank=XPR1799 | ||
|LipidMaps=LMFA03010128 | |LipidMaps=LMFA03010128 | ||
|SysName=6R, | |SysName=(6R,9alpha) -Epoxy- (11alpha,15S) -dihydroxy-prost-trans-13-en-1-oic acid | ||
|Common Name=&& | |Common Name=&&6alpha-Prostaglandin I_1&&(6R,9alpha) -Epoxy- (11alpha,15S) -dihydroxy-prost-13(E)-en-1-oic acid&& | ||
|Source= | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
|Biological Activity=6 alpha -PGI1 is reported to promote cAMP accumulation in human thyroied slices and cells in a concentration dependent manner.[[Reference:Leighton_JK:DeBrunner-Vossbrinck_BA:Kemper_B:,Biochemistry,1984,23,204|{{RelationTable/GetFirstAuthor|Reference:Leighton_JK:DeBrunner-Vossbrinck_BA:Kemper_B:,Biochemistry,1984,23,204}}]] And also exhibits 6 alpha -PGI1 inhibition of ADP-induced platelet aggregation at the IC50 value of 350 ng/ml.[[Reference:Whittle_BJ:Moncada_S:,Adv. Exp. Med. Biol.,1984,164,193|{{RelationTable/GetFirstAuthor|Reference:Whittle_BJ:Moncada_S:,Adv. Exp. Med. Biol.,1984,164,193}}]] | |||
}} | }} | ||
{{Lipid/Footer}} |
Latest revision as of 08:15, 21 October 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1799 |
LipidMaps | LMFA03010128 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20107PG20 |
6α-Prostaglandin I1 | |
---|---|
Structural Information | |
(6R,9α) -Epoxy- (11α,15S) -dihydroxy-prost-trans-13-en-1-oic acid | |
| |
Formula | C20H34O5 |
Exact Mass | 354.240624198 |
Average Mass | 354.48096000000004 |
SMILES | C(CC[C@H](O)C=C[C@H]([C@H]12)[C@H](O)C[C@H](O[C@@H](C2)CCCCC(O)=O)1)CC |
Physicochemical Information | |
6 alpha -PGI1 is reported to promote cAMP accumulation in human thyroied slices and cells in a concentration dependent manner. Leighton_JK et al. And also exhibits 6 alpha -PGI1 inhibition of ADP-induced platelet aggregation at the IC50 value of 350 ng/ml. Whittle_BJ et al. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|